Major pharmaceutical groups are becoming increasingly transparent about their growth ambitions in China, despite various diplomatic tensions between their home markets and Beijing.
In the current quarter, Pfizer (US:PFE) has revealed plans to market 12 innovative drugs in the country in 2025, while an AstraZeneca (AZN) executive has reportedly vowed the company will be a patriotic force in China that “loves the communist party”.
At the same time, home-grown Chinese options are catching up so US and European pharma giants may have a fight on their hands for the country's still-growing drug market.